Allen Institute for Artificial Intelligence
supp.ai logo
supp.ai

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 5 years ago

Possible Interaction: Insulin and Kaempferol

drug:

Insulin

supplement:

Kaempferol

Research Papers that Mention the Interaction

“Furthermore, insulin also abated the effect of kaempferol on cell viability and apoptosis in ox-LDL-induced HUVECs.”
Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology  •  2017  |  View Paper
“The above findings were reinforced by the fact that luteolin was able to abrogate the effect of insulin on the Akt/GSK-3β/Cyclin D1 pathway, resulting in suppression of insulin-induced cell proliferation.”
Cancer letters  •  2010  |  View Paper
“Oral administration of quercetin, luteolin , and EGCG impaired glucose tolerance and blunted the effect of insulin to low blood glucose.”
Inflammation  •  2012  |  View Paper
“ Luteolin modulated the Ser/Thr phosphorylation of insulin receptor substrates-1 and restored downstream Akt/eNOS activation, resulting in increased NO production in the presence of insulin.”
Biochimie  •  2011  |  View Paper
“Thus, our data suggest that luteolin influences insulin action and production of adipokines/cytokines in adipocytes by activating the PPARγ pathway.”
The Journal of nutritional biochemistry  •  2010  |  View Paper
“Conclusions: These results illustrate that luteolin attenuates inflammatory responses in the adipocytes through suppression of NF-κB and MAPKs activation, and also improves insulin sensitivity in 3T3-L1 cells, suggesting that luteolin may represent a therapeutic agent to prevent obesity-associated inflammation and insulin resistance.”
“Furthermore, luteolin improved the insulin sensitivity by enhancing the expression of insulin receptor substrates (IRS1/2) and glucose transporter-4 via phosphatidylinositol-3K signaling pathway.”
Pharmacognosy magazine  •  2015  |  View Paper